• Login
    • Join
  • FOLLOW:
  • Subscribe Free
    • Magazine
    • eNewsletter
    Checkout
    • Magazine
    • News
    • Manufacturing
    • Packaging
    • Development
    • Compliance
    • Top 25
    • Directory
    • Microsites
    • Events
    • More
  • Magazine
  • News
  • Manufacturing
  • Packaging
  • Development
  • Compliance
  • Top 25
  • Directory
  • Microsites
  • Events
  • Current / Back Issue
    Features
    Editorial
    Columns
    Digital Edition
    eNewsletter Archive
    Our Team
    Editorial Guidelines
    Subscribe Now
    Advertise Now
    Top Features
    Hygienic Packaging Technology

    Trends in Solid Oral Dosage Delivery

    5 Reasons Paper Has No Place in Contract Manufacturing

    Injectable Drug Delivery Trends

    Pharmaceutical Manufacturing Equipment Trends
    Breaking News
    Online Exclusives
    Industry News
    Collaborations & Alliances
    Promotions & Moves
    Trials & Filings
    Financial Reports
    Bio News & Views
    Custom Sourcing News
    Packaging & Tracking
    CRO News
    Live From Shows
    Top News
    Jubilant Therapeutics Appoints Chief Scientific Officer

    Iontas and Fair Journey Biologics Partner with Quell Therapeutics

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production
    APIs
    Aseptic Processing
    Cleaning Validation
    Clinical Trial Materials
    Cytotoxics and High Potency Manufacturing
    Equipment
    Excipients
    Extractables and Leachables
    Facilities
    Fill/Finish
    Lyophilization
    Parenterals
    Process Development
    Process Validation
    Risk Management
    Scale-up/ Technology Transfer
    Solid Dosage/ Creams/ Ointments

    Vetter Establishes Office in China

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie

    Fujifilm Breaks Ground on Major Expansion of Biologics Facility in Denmark
    Capsules
    Cold Chain Management
    Injectables
    Logistics
    Serialization
    Solid Dosage / Semi-solids
    Supply Chain
    Vials

    Reed-Lane Facility Virtual Tour

    Hygienic Packaging Technology

    Reshaping the Pharmaceutical Supply Chain

    Serialization: Level 5 Solution

    Covectra Introduces Next-Gen Serialization Solution
    Analytical Services
    Bioanalytical Services
    Bioassay Developement
    Biologics, Proteins, Vaccines
    Biosimilars
    Chemistry
    Clinical Trials
    Drug Delivery
    Drug Development
    Drug Discovery
    Formulation Development
    Information Technology
    Laboratory Testing
    Methods Development
    Microbiology
    Preclinical Outsourcing
    R&D
    Toxicology

    Vetter Establishes Office in China

    Data Management Trends

    AGC Biologics Expands Cell and Gene Facility in Italy

    Celonic to Boost Cell & Gene Therapy Production

    Pharmaron Acquires Biomanufacturing Site in the UK from AbbVie
    Filtration & Purification
    GMPs/GCPs
    Inspections
    QA/QC
    Regulatory Affairs
    Validation

    Guide to Maintaining Validation of Older Facilities: Why, When and How

    The Year of COVID: How FDA Coped with a Worldwide Pandemic in 2020 and What to Expect in 2021

    Top BioPharma Form Accumulus Synergy

    Global Biosciences Co. Selects ValGenesis VLMS

    Gene Therapy Co. Selects ValGenesis' SaaS Platform
    Companies
    Categories
    Corporate Capabilities
    Add New Company
    Contract Service Directory Companies
    Adare Pharma Solutions

    PCI Pharma Services

    Baxter BioPharma Solutions

    Syngene

    Reed-Lane
    Companies
    News Releases
    Posters
    Brochures
    Services
    Videos
    Case Study
    White Papers
    Jobs
    Contract Service Directory Companies
    Adare Pharma Solutions

    Syngene

    Cytovance Biologics

    Almac Group

    Baxter BioPharma Solutions
    Webinars
    Live From Shows
    • Magazine
      • Current / Back Issue
      • Features
      • Editorial
      • Columns
      • Editorial Guidelines
      • Subscribe Now
      • Advertise Now
      • Enewsletter Archive
      • Digital Edition
    • Directory
      • Companies
      • Categories
      • Corporate Capabilities
      • Add Your Company
    • Manufacturing
      • APIs
      • Aseptic Processing
      • Cleaning Validation
      • Clinical Trial Materials
      • Cytotoxics and High Potency Manufacturing
      • Equipment
      • Excipients
      • Extractables and Leachables
      • Facilities
      • Fill/Finish
      • Lyophilization
      • Parenterals
      • Process Development
      • Process Validation
      • Risk Management
      • Scale-up/ Technology Transfer
      • Solid Dosage/ Creams/ Ointments
      • cGMP Manufacture
    • Packaging
      • Capsules
      • Cold Chain Management
      • Injectables
      • Logistics
      • Serialization
      • Solid Dosage / Semi-solids
      • Supply Chain
      • Vials
    • Development
      • Analytical Services
      • Bioanalytical Services
      • Bioassay Developement
      • Biologics, Proteins, Vaccines
      • Biosimilars
      • Chemistry
      • Clinical Trials
      • Drug Delivery
      • Drug Development
      • Drug Discovery
      • Formulation Development
      • Information Technology
      • Laboratory Testing
      • Methods Development
      • Microbiology
      • Preclinical Outsourcing
      • R&D
      • Toxicology
    • Compliance
      • Filtration & Purification
      • GMPs/GCPs
      • Inspections
      • QA/QC
      • Regulatory Affairs
      • Validation
    • Top 25 Pharma & BioPharma
    • Contract Pharma Direct
    • Breaking News
    • Online Exclusives
    • Slideshows
    • Experts Opinions
    • Surveys
      • Outsourcing Survey
      • Salary Survey
    • Glossary
    • Videos
    • Podcasts
    • White Papers
    • Infographics
    • Contract Pharma Conference
      • Contract Pharma Conference
      • Speakers
      • Exhibitors
      • Conference Sessions
    • Supplier Microsite
      • Companies
      • News Releases
      • Posters
      • Brochures
      • Services
      • Videos
      • Case Study
      • White Papers
    • eBook
    • Webinars
    • Events
      • Industry Events
      • Live from Show Events
      • Webinars
    • Classifieds / Job Bank
      • Classifieds
      • Job Bank
    • About Us
      • About Us
      • Contact Us
      • Advertise With Us
      • Privacy Policy
      • Terms of Use
    Features

    PAI Readiness – A Journey, not an Event

    A look at what you need to do to get ready for a pre-approval inspection

    PAI Readiness – A Journey, not an Event
    Related CONTENT
    • Vetio Animal Health
    • Semi-Solids: A Regulatory Perspective
    • Stellar Announces Positive Third-Party Trial Results
    • Cytovance Biologics Completes FDA Inspection
    • Janssen's Supply Chain VP Talks Trends
    Dr. Walter Matzmorr, Tunnell Consulting06.12.18
    Being ready for a Pre-Approval Inspection (PAI) is a key milestone for the successful approval of a new product and can significantly impact the approval timeline and time to market. For companies who have experience in product development and commercialization, getting ready for a PAI is built into their development process, but small companies and biotech startups who want to get their first product approved often struggle to determine if they are ready for a PAI. Avoiding this uncertainty requires thorough preparation. Utilizing external, independent reviews and assessments minimizes the risk of surprises and maximizes the best use of limited internal resources.

    PAI readiness is not a one-time event that can be achieved through assessments and training alone; it is a cross-functional process with multiples phases that include elements of technical and regulatory compliance, organizational aspects, training, and product, process, and method validation.

    The FDA conducts a PAI to ensure that a manufacturing establishment named in a drug application is capable of manufacturing and/or testing a drug and that the submitted data are accurate and complete.

    What does this mean for the main objectives for a PAI? Being capable of manufacturing a drug includes the methods or processes, the facilities and the controls used to manufacture a drug. It requires compliance with CGMP regulations, robust product, process and method validation, adequately established quality systems, an appropriate quality risk management system as well as compliance with other applicable, process or product specific regulations. However, being capable of manufacturing a product is by far not enough to pass a PAI. During the PAI, the FDA will verify that the actual process including test methods are in conformance with the original application and that the established approach and practices for data management ensure the integrity of the data that have been generated and used in development, manufacturing, monitoring and product testing. All this will be assessed during a PAI so that the main objectives can be summarized as follows:
    • Confirm the Readiness for Commercial Manufacturing
    • Verify the Conformance to Application
    • Verify Data Integrity / Conduct a Data Integrity Audit
    Figure 1 shows how these objectives are interconnected with each other.


    Figure 1. Interconnected Objectives of a PAI

    Risk-based approach
    The three main objectives of a PAI cover a wide field that spans for a new product from the development phase to the current manufacturing footprint, which very often includes third party manufacturing sites and contract testing labs. However, there are situations, where PAIs can be more limited like in the case of a change in the manufacturing site or a major process change. This is why the FDA typically applies risk based priority inspection criteria, making the inspection breadth decision based on the following risks:
    • Facility Risk
    • Product Risk
    • Process Risk
    A startup company with a new product and new process technology in a new facility scores high in all risk areas listed above, whereas in the case of a transfer of an approved product to a brand-new facility, facility risks would be the primary focus.

    The journey
    Typically we see two different scenarios in which sites or organizations need to prepare for a PAI.

    Scenario 1. For established organizations experienced in CGMP operations and experienced in PAIs, a Mock PAI that simulates a real inspection situation is typically the way to go. The Mock PAI should include inspection training and coaching. Any findings or observations during the Mock PAI should be addressed accordingly.

    Scenario 2. For organizations with no or limited CGMP experience that are preparing for their first PAI, a one-time status check in the form of a Mock Inspection is predictably insufficient. In these cases, the PAI preparation needs to include a significant transformation moving out of a research and development environment and mindset into the CGMP, commercial production world. This transformation challenges many parts of the organization, but it is a fundamental change that should be carefully reflected and embedded into the overall preparation plan.

    Because a PAI is a critical milestone for any company, an approach that includes the sustainable and long-term development of PAI Readiness minimizes the risk of any PAI, but this requires advanced, appropriate planning to meet the key milestones on the journey to PAI Readiness.

    The journey towards PAI preparedness incorporates the following milestones:
    1. Technical Readiness
    2. GMP Readiness
    3. PAI Readiness
    In cases described in Scenario 1, technical readiness and GMP readiness are theoretically already successfully established and PAI Readiness could be verified through assessments,  audits and a Mock Inspection, but for “first timers” as described in Scenario 2 this journey is an endeavor that takes significant time and resources. As with every journey into new territory a roadmap and guidance from experienced travelers helps ensure that all critical milestones are met and that the final destination is reached on time. Figure 2 shows a high level timeline and key milestones on the journey towards PAI readiness and a successful PAI.


    Figure 2. Steps towards PAI Readiness

    Depending on the situation, it can take up to two years or more to achieve PAI Readiness. This estimation includes the time to get a facility to Technical Readiness and to train personnel and establish proper procedures and supporting quality systems to ensure compliance with CGMPs.

    For start-up companies, the main challenge is to ensure that during this timeframe all elements that are critical to achieve Technical Readiness and GMP Readiness have been sufficiently addressed. Otherwise, the Mock inspection could uncover critical issues that would potentially impact the chances of a timely and successful PAI.

    The first step is to ensure that a facility achieves the Technical Readiness milestone for technical transfer and engineering runs. This requires that the equipment is installed and operates as intended. This should be verified through successful commissioning and qualification, planned and successfully executed based on a pre-defined and pre-approved Commissioning and Qualification plan. At this point, it is also required that the process description is in final draft form. Additionally, the basic outline of the process validation plan and the process control strategy should have been developed and that appropriate test methods, change control procedures and good documentation practices are in place.

    The second milestone, GMP Readiness, is achieved when the process description and the master batch records are finalized, the process control strategy has been defined and appropriate, sustainable quality systems are implemented. The verification of GMP Readiness typically requires area-specific audits, comprehensive training programs and coaching, where appropriate. From a practical perspective it should be considered that at this point critical aspects of future manufacturing performance and efficiency will be defined. All facility, manufacturing and testing related processes need to be established.  It should be verified to ensure that they are compliant with applicable CGMP regulations, but it should be also verified that they are “fit for purpose.” This applies to manufacturing and supporting process-related SOPs, Master Batch Records, environmental monitoring programs, and governing quality systems. They need to be designed in a way that all processes and procedures are clearly defined and efficient and ensure compliance. Most of us have seen batch records with 150 pages and more, but also examples with about 50 pages for comparable processes. It is also very likely that many, if not all, of us have seen change control and deviations investigation forms that are signed off by more individuals than the Declaration of Independence. It is much easier and more efficient to implement a streamlined process with clear roles and responsibilities from the beginning rather than trying to optimize it at a later point in time.  Bringing experienced coaches on board that know what to do, how to do it and when to do it, adds value, ensures that CGMP compliance, efficiencies, and “fit for purpose” are aligned while preparing for GMP readiness.

    Once the two first milestones have been achieved the final phase to PAI Readiness typically includes inspection training and coaching to ensure that the logistical and organizational challenges for the PAI are understood and that the site team is properly prepared to manage them.

    Hands-on training and coaching for inspection situations in different areas should be included and cover all levels of a site organization from site management to shop floor operators. Experienced coaches can provide guidance on how to respond to questions and how to handle different types of inspectional situations as well as managing the overall inspection process. The final litmus test is a Mock Inspection, which simulates a real inspection situation. Once the Mock Inspection has been executed and any potential findings of the inspection have been suitably addressed, the goal of PAI Readiness has been achieved.

    Table 1 summarizes the main elements for each Readiness Milestone that need to be in place.


    Table 1. Milestones to PAI Readiness

    Conclusion
    PAI Readiness has a lot of challenging aspects especially for young organizations and/or “first timers.” Like many other things that are done for the first time, it comes with a level of uncertainty. Successful preparation of PAI Readiness requires well-informed planning and diligent preparation. A PAI is much more than a routine GMP inspection that the FDA conducts on a regular basis. A PAI is the final verification that a company has the right procedures and processes in place to manufacture a product under CGMPs and that the actual process conditions and parameters are in conformance with the product filing.

    The level of complexity and experience of the organization dictates the time required for planning in advance of an expected PAI to avoid last minute surprises. The use of experienced coaches who can act as guides and advisors is a way to minimize PAI inspection risks and also to ensure that process controls and quality systems are “fit for purpose,” compliant and efficient from the start. 


    Dr. Walter Matzmorr has more than 30 years’ experience in process development, manufacturing and engineering within the biopharmaceutical industry. His expertise includes aseptic processing, filling and lyophilization, good manufacturing practices (GMP), and process optimization and facility start up. He also has in-depth experience in dealing with regulatory agencies in the U.S. and Europe. walter.matzmorr@tunnellconsulting.com
    Related Searches
    • Development
    • Aseptic
    • quality
    • Manufacturing
    Suggested For You
    Vetio Animal Health Vetio Animal Health
    Semi-Solids: A Regulatory Perspective Semi-Solids: A Regulatory Perspective
    Stellar Announces Positive Third-Party Trial Results Stellar Announces Positive Third-Party Trial Results
    Cytovance Biologics Completes FDA Inspection Cytovance Biologics Completes FDA Inspection
    Janssen Janssen's Supply Chain VP Talks Trends
    Drug Safety Update Drug Safety Update
    Finding Value in Quality Contract Manufacturing Finding Value in Quality Contract Manufacturing
    From OMUFA To Opioids From OMUFA To Opioids
    Sterile Fill & Finish Sterile Fill & Finish
    HHS 2019 Budget Proposal: Key Priorities Impacting Pharma HHS 2019 Budget Proposal: Key Priorities Impacting Pharma
    Cellenkos Completes FDA Registration of GMP Mfg. Facility Cellenkos Completes FDA Registration of GMP Mfg. Facility
    Pii Receives 7 Market Approvals from FDA in 2017 Pii Receives 7 Market Approvals from FDA in 2017
    An Interactive Global Map of Pharma Manufacturing Sites An Interactive Global Map of Pharma Manufacturing Sites
    Sobi Receives IND Acceptance from FDA Sobi Receives IND Acceptance from FDA
    Cytovance Hires Quality VP Cytovance Hires Quality VP

    Related Features

    • Solid Dosage/Semi-solids
      Hygienic Packaging Technology

      Hygienic Packaging Technology

      Growing consumer demand for health products highlights hygienic packaging.
      John Brown, Vice President of Global Marketing, Selig 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Trends in Solid Oral Dosage Delivery

      Trends in Solid Oral Dosage Delivery

      Capsule demand continues to rise due to this delivery system’s versatility.
      Anita Solanki, Milind Biyani and Jnanadeva Bhat, PhD , ACG Capsules 03.01.21

    • Information Technology
      5 Reasons Paper Has No Place in Contract Manufacturing

      5 Reasons Paper Has No Place in Contract Manufacturing

      Digital solutions create more efficient manufacturing processes and eliminate delays.
      Dave Edwards, Chief Revenue Officer, MasterControl 03.01.21


    • Drug Delivery | Parenterals
      Injectable Drug Delivery Trends

      Injectable Drug Delivery Trends

      How medication trends are driving the shift to patient-friendly drug delivery systems.
      Peter Soelkner, Managing Director, Vetter 03.01.21

    • Pharmaceutical Manufacturing  Equipment Trends

      Pharmaceutical Manufacturing Equipment Trends

      Demand for flexibility remains the driving force behind equipment systems.
      Kristin Brooks, Managing Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Oral Solids:   Market & Technology Trends

      Oral Solids: Market & Technology Trends

      Oral solids remain the preferred route of drug delivery due to their cost-effectiveness, ease of manufacturing, and patient-friendly dose form options.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • Nutraceutical Manufacturing:  Meeting the Challenges of Today, Planning for  Tomorrow

      Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow

      Companies continue balancing high demand, supply disruption, and worker safety during the pandemic.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • 2021 Contract  Manufacturing Survey

      2021 Contract Manufacturing Survey

      Our fourth annual audience poll indicates continued reliance on manufacturing partners, particularly for small businesses.
      Sean Moloughney, Editor, Nutraceuticals World 03.01.21

    • APIs
      Small Molecule Development Trends

      Small Molecule Development Trends

      A Q&A with Cambrex Edinburgh’s site director, Mark Benger.
      Tim Wright, Editor, Contract Pharma 03.01.21


    • APIs | Cytotoxics and High Potency Manufacturing
      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      Challenges & Opportunities Facing Small & Emerging Biopharma Companies

      A Q&A with Christian Dowdeswell, vice president and head of commercial development for small molecules at Lonza.
      Tim Wright, Editor, Contract Pharma 03.01.21

    • Drug Delivery | Solid Dosage/Creams/Ointments
      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Medicated Chewing Gum: A Modern Oral Drug Delivery System

      Development and manufacture of medicated chewing gum continues to gain momentum.
      Rukayat Adedeji, Contributing Writer 03.01.21

    • APIs
      Small Molecule API CDMO: A Capital Intensive Business?

      Small Molecule API CDMO: A Capital Intensive Business?

      Exploring small molecule API market trends.
      Dr. Michele Jermini and Dr. Enrico Polastro, Contributing Writers 03.01.21


    • Serialization
      Serialization: Level 5 Solution

      Serialization: Level 5 Solution

      Why a Level 5 solution is required for small pharma companies to fully harness serialization investment.
      Steve Wood, President & CEO, Covectra 03.01.21

    • Solid Dosage/Creams/Ointments
      High Drug Loading Amorphous Solid Dispersions

      High Drug Loading Amorphous Solid Dispersions

      A Novel Tablet Architecture for Amorphous Solid Dispersions to Achieve High Drug Loadings
      Deanna Mudie and Aaron Stewart, Lonza 01.27.21

    • Parenterals
      Parenteral Drug Delivery Trends

      Parenteral Drug Delivery Trends

      A Q&A with Lubrizol Life Science Health’s CDMO Division President, Rob Lee.
      Kristin Brooks, Managing Editor, Contract Pharma 01.27.21

    Trending
    • Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement For Novavax’ COVID-19 Vaccine
    • Four Female Leaders Appointed To Cell & Gene CDMO
    • Pharmaron Acquires Biomanufacturing Site In The UK From AbbVie
    Breaking News
    • Jubilant Therapeutics Appoints Chief Scientific Officer
    • Iontas and Fair Journey Biologics Partner with Quell Therapeutics
    • Vetter Establishes Office in China
    • AGC Biologics Expands Cell and Gene Facility in Italy
    • Celonic to Boost Cell & Gene Therapy Production
    View Breaking News >
    CURRENT ISSUE

    March 2021

    • Hygienic Packaging Technology
    • Trends in Solid Oral Dosage Delivery
    • 5 Reasons Paper Has No Place in Contract Manufacturing
    • Injectable Drug Delivery Trends
    • Pharmaceutical Manufacturing Equipment Trends
    • Oral Solids: Market & Technology Trends
    • Nutraceutical Manufacturing: Meeting the Challenges of Today, Planning for Tomorrow
    • 2021 Contract Manufacturing Survey
    • Small Molecule Development Trends
    • Challenges & Opportunities Facing Small & Emerging Biopharma Companies
    • View More >

    Cookies help us to provide you with an excellent service. By using our website, you declare yourself in agreement with our use of cookies.
    You can obtain detailed information about the use of cookies on our website by clicking on "More information”.

    • About Us
    • Privacy Policy
    • Terms And Conditions
    • Contact Us

    follow us

    Subscribe
    Nutraceuticals World

    Latest Breaking News From Nutraceuticals World

    Diets High In Fructose Could Cause Immune System Damage
    Nestlé Acquires Premium Water Brand Essentia
    Kaneka Probiotics Announces Launch of L. plantarum DR7
    Coatings World

    Latest Breaking News From Coatings World

    Sherwin-Williams Announces Resignation of President, COO
    Ashland Completes Expansion, Relocation of Viatel Bioresorbable Polymers Manufacturing Facility
    Evonik Receives Sustainability Award from EcoVadis
    Medical Product Outsourcing

    Latest Breaking News From Medical Product Outsourcing

    FDA OKs First OTC Home Molecular COVID-19 Test
    FDA Approves Second Sight's Argus 2s Retinal Prosthesis
    Cross Border Venture Financing Rose in Final Quarter of 2020
    Contract Pharma

    Latest Breaking News From Contract Pharma

    Sharp Appoints EU Qualified Person
    Baxter Biopharma Solutions Enters Sterile Manufacturing Agreement for Novavax’ COVID-19 Vaccine
    Metrics Contract Services Completes Russian Regulatory Inspection
    Beauty Packaging

    Latest Breaking News From Beauty Packaging

    It's International Women's Day—But What Does That Mean?
    e.l.f. Cosmetics and Chipotle Collaborate on Burrito-Inspired Makeup Collection
    Weekly Recap: Sephora Expansion, Ulta Partners with Loop, International Women’s Day & More
    Happi

    Latest Breaking News From Happi

    Cococare Appoints First Woman President
    Ross Highlights Triple Shaft Mixers
    Arm & Hammer Unveils Foot Wipes
    Ink World

    Latest Breaking News From Ink World

    Capital Printing Invests in 2nd Komori Press
    Arna Marketing Adds Canon’s ProStream, VarioPRINT iX Production Inkjet Presses
    Massilly North America Adds Koenig & Bauer MetalStar 3 Metal Decorating Press
    Label & Narrow Web

    Latest Breaking News From Label & Narrow Web

    Xeikon details upcoming Xeikon Café TV seminars
    Resource Label Group acquires New England Label
    UV+EB-cured products rated 'easier to recycle'
    Nonwovens Industry

    Latest Breaking News From Nonwovens Industry

    Arm & Hammer Launches Foot Wipes
    Kimberly-Clark Names Chief Research and Development Officer
    FPInnovations Develops Biodegradable Mask
    Orthopedic Design & Technology

    Latest Breaking News From Orthopedic Design & Technology

    Australia Clears Conformis' iTotal PS Knee Replacement System
    Colfax Decides to Divide Its Businesses
    Stryker Corp.'s 2020 Sales Slip 3.6 Percent
    Printed Electronics Now

    Latest Breaking News From Printed Electronics Now

    Comercial Kywi Improves Customer Service, Front-Store Operations with Zebra Mobile Solution
    Global Smart Glass Market to Register 6.8% CAGR Between 2021-28: Grand View Research
    Wearable Patch Market to Reach $27.8 Billion by 2027: Allied Market Research

    Copyright © 2021 Rodman Media. All rights reserved. Use of this constitutes acceptance of our privacy policy The material on this site may not be reproduced, distributed, transmitted, or otherwise used, except with the prior written permission of Rodman Media.

    AD BLOCKER DETECTED

    Our website is made possible by displaying online advertisements to our visitors.
    Please consider supporting us by disabling your ad blocker.


    FREE SUBSCRIPTION Already a subscriber? Login